去甲氧柔红霉素联合阿糖胞苷治疗急性髓系白血病的临床疗效

目的：探讨急性髓系白血病患者采用去甲氧柔红霉素联合阿糖胞苷治疗的临床疗效。方法70例急性髓系白血病患者按照随机数字表法分为对照组与治疗组，各35例。对照组采用柔红霉素治疗。治疗组采用去甲氧柔红霉素治疗。比较2组临床疗效、生存质量、毒副作用。结果治疗后治疗组治疗有效率为45．71％（16／35）与对照组[40．00％（14／35）]比较P＞0．05；治疗组治疗获益率为57．14％（20／35），明显高于对照组[45．71％（16／35）]（P＜0．05）；2组患者KPS改善率比较（P＜0．05）。治疗组治疗期间不良反应发生率为48．57％（17／35）明显低于对照组[77．14％（27／35）]（P＜0．05）。结论去甲氧柔红霉素联合阿糖胞苷治疗急性髓系白血病患者的临床总体疗效较好，且显著改善患者生存质量，减少不良反应，值得推广应用。

Clinical Efficacy of Idarubicin and Cytarabine for Acute Myelogenous Leukemia

Objective To discuss the clinical efficacy of idarubicin and cytarabine for acute myelogenous leukemia. Methods 70 patients with acute myelogenous leukemia were equally divided into the control group and the treatment group ac-cording to random number table.The control group received daunorubicin,while the treatment group received idarubicin.Clinical effects,quality of life and side effects of the 2 groups were compared.Results After treatment,the response rate of the treatment group was [45.71%(16/35)] and that of the control group was[40.00%(14/35)] (P>0.05);the benefit rate of the treat-ment group was 57.14%(20/35),which was higher than that of the control group [45.71% (16/35)] (P<0.05);the KPS improvement rate of the 2 groups had significant difference,P<0.05.Conclusion Idarubicin and cytarabine for acute myeloge-nous leukemia is effective,and it can significantly improve patients'quality of life,and reduce adverse reactions.Therefore,it is worthy of promotion.